We want to compare duplicate measurements of celite ACT and kaolin ACT in patients undergoing cardiac surgery. In addition we want to measure heparin use during surgery in patients monitored with celite ACT and with kaolin ACT.In addition,…
ID
Source
Brief title
Condition
- Therapeutic procedures and supportive care NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
the total amount of heparin given in each group.
Secondary outcome
fibrinopeptide A and postoperative blood loss
Background summary
Anticoagulation during cardiac surgery is point of care monitored using the
activated clotting time (ACT) as described by Bull [1]. As an activator for
this measurement either celite or kaolin is used. Both activators are used
routinely in clinical practice. However, there is doubt about the reliability
of each measurement. In addition, a review of patient charts suggests that
kaolin ACT has less variability than celite ACT.
Study objective
We want to compare duplicate measurements of celite ACT and kaolin ACT in
patients undergoing cardiac surgery. In addition we want to measure heparin use
during surgery in patients monitored with celite ACT and with kaolin ACT.
In addition, preliminary data suggest that platelet function influences ACT
measurements.
Additionally, platelet function will be monitored by means of aggregometry to
reveal how this influences the ACT values
Study design
Randomized prospective single blinded clinical trial. 125 Patients are
allocated to either group one(n50): heparin management is guided by celite act
or group two(n50): heparin management is guided by kaolin act.
group3(25) ADDITIONAL HEPARIN MANAGEMENT IS GUIDED BY Junior measurements
Study burden and risks
in total 49mL blood will be taken from the heart lung machine.
There are no risks associated with participation as both monitoring
measurements are routinely used during cardiac surgery.
Patients will not individually benefit from participation.
hanzeplein 1 hanzeplein 1
Groningen 9700RB
AF
hanzeplein 1 hanzeplein 1
Groningen 9700RB
AF
Listed location countries
Age
Inclusion criteria
Patients presenting for coronary artery bypass grafting and/or valve repair/replacement.
Exclusion criteria
Patients with heredetary coagulopathies. Patients pre-operatively treated with unfractionated heparin.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL17568.042.07 |